• Home
  • About KinaseCentral

Kinase News

Entries RSS | Comments RSS
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines
  • Tags

    AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
  • Providing a resource for information on kinase inhibitors

Phase III Avastin trial in Colon Cancer to continue

Posted on October 20, 2008 by crimsoncanary

Genentech have announced that its ongoing Phase III study of Avastin (bevacizumab) in patients with early-stage colon cancer will continue as planned.

Filed under: Uncategorized | Tagged: Avastin, bevacizumab, Genentech, kinase, phase iii, Roche, VEGF

« Enzon to present new ErbB3 RNAi at EORTC-NCI-AACR Boehringer Ingelheim PLK1 inhibitor BI6727 effective in Phase I »
  • Calendar

    • October 2008
      M T W T F S S
      « Sep    
       12345
      6789101112
      13141516171819
      20212223242526
      2728293031  
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer